Table 3.
Multivariate analysis of PFS and OS in all patients (N = 163)
| Cox’s regression for PFS | Cox’s regression for OS | |||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% Cl | P value | PA | HR | 95% Cl | P value | PA | |
| Gender | ||||||||
| Male vs female | 1.74 | 0.82–3.69 | 0.15 | 0.535 | 1.31 | 0.26–6.44 | 0.75 | 0.548 |
| ISUP | ||||||||
| ≥ 3 vs < 3 | 2.21 | 0.89–5.47 | 0.09 | 0.568 | 12.8 | 0.72–227.37 | 0.08 | 0.595 |
| Nephrectomy | ||||||||
| Yes vs No | 0.46 | 0.12–1.67 | 0.24 | 0.561 | 0.22 | 0.03–1.73 | 0.15 | 0.578 |
| ECOG score | ||||||||
| ≥ 2 vs 1 | 0.73 | 0.28–1.91 | 0.51 | 0.580 | 1.62 | 0.11–25.78 | 0.73 | 0.572 |
| IMDC | 0.656 | 0.647 | ||||||
| Low | Ref. | Ref. | 0.04 | Ref. | Ref. | 0.87 | ||
| Intermediate | 1.15 | 0.48–2.78 | 0.76 | 1.08 | 0.11–10.29 | 0.95 | ||
| High | 3.98 | 1.14–13.92 | 0.03 | 0.55 | 0.02–14.58 | 0.72 | ||
| Synchronic metastasis | ||||||||
| Yes vs No | 0.99 | 0.51–1.89 | 0.97 | 0.618 | 65.6 | 2.28–1888.34 | 0.02 | 0.674 |
| BMI | 1.47 | 0.98–2.21 | 0.06 | 0.615 | ||||
| Laboratory parameters | ||||||||
| WBC | 1.01 | 0.99–1.02 | 0.35 | 0.513 | 1.003 | 0.97–1.04 | 0.87 | 0.610 |
| PD-1 positive (P or M)a | 1.27 | 0.62–2.61 | 0.51 | 0.554 | ||||
| Cox model without PD-1 | 0.683 | 0.747 | ||||||
| Cox model with PD-1 | 0.699 | |||||||
aP or M, primary or metastatic tumor
Abbreviations: ISUP International Society of Urological Pathology, ECOG Eastern Cooperative Oncology Group, IMDC International Metastatic Renal-Cell Carcinoma Database Consortium, BMI Body Mass Index